Teva launches generic for Pfizer’s Flector pain patch

Teva (NYSE:TEVA) said last week that it launched a generic version of Pfizer‘s (NYSE:PFE) Flector diclofenac epolamine patch.

Using a nonsteroidal anti-inflammatory drug, the topical patch is designed to treat acute pain due to minor strains, sprains and contusions.

Pfizer’s Flector patch garnered annual sales of $123 million in the U.S. as of Dec. 2018, according to IQVIA.

“The launch of our authorized generic of Flector Patch in the U.S. is an important addition to Teva’s portfolio of over 40 generic pain management medicines,” Brendan O’Grady, EVP & head of Teva’s North America commercial division, said in prepared remarks.

Last month, Teva reported that it expects its generic EpiPen auto-injector to hold 25% of the U.S. market by the end of 2019.

Mylan‘s (NSDQ:MYL) brand-name emergency allergy device has dominated the U.S. market for years. After Mylan faced widespread criticism for the price of its EpiPen product, the company launched its own generic for roughly $300.

Teva launched its generic EpiPen auto-injector in November, but priced the product in line with Mylan’s EpiPen generic.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Theranos whistleblower Tyler Shultz to participate in keynote interview at DeviceTalks Boston At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos. Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston. REGISTER NOW